Axicabtagene ciloleucel (Yescarta) — CAR-T treatment for lymphoma

What is axicabtagene ciloleucel (Yescarta) in simple words

Axicabtagene ciloleucel, sold as Yescarta, is not a tablet and not a usual infusion drug. It is a CAR-T treatment made from the patient’s own immune cells.

The idea is fairly direct. Blood cells are collected, the T-cells are changed in a laboratory, and then returned to the body with a new task: to recognise lymphoma cells carrying CD19.

That sounds neat on paper. In real life it is a demanding treatment. It needs a trained centre, time for cell production, careful monitoring and a patient who can safely get through the first weeks after infusion.

So the question is never just “can Yescarta kill lymphoma?” The real question is whether this person, with this disease history, is at the right point for CAR-T.

How axicabtagene ciloleucel works

In many B-cell lymphomas, the malignant cells still carry a surface marker called CD19. Yescarta uses that marker as a kind of address label.

After the patient’s T-cells are collected, they are trained outside the body to look for that address. Once infused back, they can expand, move through the body and attack cells that show the target.

This is why CAR-T is different from chemotherapy. It is not a course of repeated drug cycles in the usual sense. It is a one-time cell infusion, with a long clinical tail afterwards. The important part often happens after the bag is empty.

What conditions Yescarta is used for

Yescarta may be discussed in adults with certain B-cell lymphomas, especially when earlier treatment has not given enough control.

• fast-growing B-cell lymphoma after an early return;

• DLBCL-type disease, when the picture fits;

• lymphoma starting in the mediastinal area;

• high-grade B-cell pattern;

• disease that grew out of a follicular lymphoma;

• slow B-cell lymphoma after repeated treatment rounds.

The name of the lymphoma matters. But it does not decide everything. Timing, previous response, tumour tempo and the patient’s general condition often matter just as much.

When Yescarta may be especially relevant

In practice, Yescarta usually enters the conversation when standard treatment has already shown its limits.

• early return after first treatment;

• disease still active after initial therapy;

• lymphoma back after two or more regimens;

• fast progression with few good options;

• slow B-cell lymphoma after repeated relapse;

• CD19 still present on tumour cells.

There is also a timing issue. Waiting too long can close the window. Some patients look stable at the consultation but decline quickly while more treatment is being planned. That is why referral to a CAR-T centre should not be left until the last minute.

What needs to be checked before starting treatment

Before Yescarta is seriously planned, the team usually needs a clear picture of both the lymphoma and the patient’s reserve.

• recent biopsy or pathology review;

• CD19 status if there is doubt;

• PET-CT or CT imaging;

• blood counts and chemistry;

• heart and lung assessment;

• infection screening;

• kidney and liver function;

• previous lymphoma treatments;

• current steroid or immune-suppressive drugs;

• neurological history.

A practical question is also asked early: can the patient wait for the cells to be prepared, or is some short-term bridging treatment needed? That decision is very individual. Too little treatment may allow the lymphoma to run ahead. Too much can weaken the patient before CAR-T.

How treatment is carried out

The process starts with cell collection. The patient is connected to a machine that separates out the cells needed for manufacturing. The rest of the blood is returned during the same procedure.

After that, there is a waiting period while the CAR-T product is prepared. Some patients receive temporary lymphoma control during this gap. Others can simply be observed until the product is ready.

A few days before infusion, short chemotherapy is given to make space for the returning CAR-T cells. Then Yescarta is infused once through a vein.

Monitoring after infusion is the part patients often underestimate. The first days and weeks can be unstable. The team watches for fever, blood pressure changes, confusion, breathing problems and other signs that the immune reaction is becoming too strong.

Possible side effects

CAR-T side effects are not the same as standard chemotherapy side effects. Some are caused by the immune system turning on very suddenly.

• fever and chills;

• low blood pressure;

• shortness of breath;

• confusion or sleepiness;

• speech or memory changes;

• low blood counts;

• infections;

• tiredness that can last weeks;

• liver test changes;

• seizures in rare cases.

Two problems receive special attention: an inflammatory reaction after infusion and neurological changes. Both can be treatable, but they are not symptoms to “watch for a few more days” at home. Early reporting matters.

When to contact a doctor urgently

After Yescarta, patients are usually given very clear instructions on when to call. Those instructions should be followed even if the symptom seems small at first.

• temperature or chills;

• new breathing difficulty;

• dizziness or faintness;

• confusion;

• trouble speaking;

• severe headache;

• seizure-like episode;

• fast heartbeat;

• bleeding or unusual bruising;

• sudden worsening of weakness.

A mild fever after CAR-T can be the first sign of something more serious. It may still turn out to be manageable, but the team needs to know early. This is one treatment where silence is risky.

Why Yescarta is not right for everyone

Yescarta can be powerful, but it is not a simple “stronger treatment” that fits every difficult lymphoma case.

• very poor general condition;

• uncontrolled infection;

• severe organ weakness;

• active neurological problems;

• lymphoma progressing too fast;

• loss of the CD19 target;

• no safe access to a CAR-T centre.

Sometimes the issue is not eligibility on paper. It is whether the patient can safely get through the preparation, infusion and monitoring period. That is a different kind of judgement, and it needs an experienced team.

Can Yescarta be combined with other treatments

Yescarta itself is given as a single CAR-T infusion. Around it, however, other treatments may be used.

Before infusion, doctors sometimes use bridging therapy to keep the lymphoma controlled while the cells are being prepared. After infusion, the plan depends on response, blood count recovery and complications. Some patients need infection prevention, immunoglobulin support or treatment for late immune effects.

What is usually avoided is casual mixing. CAR-T is already a complex immune treatment. Every extra drug must have a clear reason.

What “no quick response” to treatment means

With Yescarta, the first weeks can be noisy. A patient may feel worse before the scans show the full picture. Fever, weakness and hospital monitoring do not automatically mean the treatment has failed.

Response is judged by imaging, symptoms, blood tests and the overall direction of the disease. Sometimes there is a clear improvement early. Sometimes the first answer is only partial, and the next scan matters more.

The hardest part for patients is the waiting. CAR-T is a one-time infusion, but the body does not answer in one day.

Oncology consultation for Yescarta in Israel

At Tel Aviv Medical Clinic in Israel, patients can discuss whether Yescarta is a realistic option for their lymphoma situation.

A consultation may be useful when the treatment plan has become unclear, when several regimens have already been used, or when a CAR-T referral is being considered and the family wants to understand the timing.

• review of diagnosis and pathology;

• assessment of previous treatments;

• discussion of CAR-T timing;

• bridging therapy questions;

• second opinion before referral;

• planning after relapse.

The consultation does not replace the treating haematologist. It helps make the next decision clearer, especially when the window for CAR-T may be narrow.

Frequently Asked Questions — Dr. Stefanskoy

1. Is Yescarta chemotherapy?

No. It is a cell-based treatment. Chemotherapy may be used briefly before the infusion, but that is not the main therapy. The main part is the return of modified T-cells that have been prepared to recognise lymphoma cells. Patients often call everything “chemotherapy” because it all happens in oncology. Medically, this is a different category and the risks are different too.

2. Why does the treatment take time to prepare?

Because the product is made for one patient. Cells are collected, sent for manufacturing, checked, and then returned for infusion. That process cannot be rushed like ordering a standard drug from a pharmacy. During the waiting period, the team decides whether the lymphoma can safely be watched or needs temporary treatment.

3. Does Yescarta work for every lymphoma?

No. It is mainly relevant when the lymphoma belongs to the B-cell group and still carries the target the CAR-T cells are looking for. Even then, the details matter. A slow follicular lymphoma and a fast aggressive lymphoma create different clinical questions. I always start with the pathology, the PET-CT and the treatment history before discussing CAR-T seriously.

4. What is the biggest early risk after infusion?

The first concern is an intense immune reaction. It may start with fever, but it can move into low blood pressure, breathing problems or confusion. This is why CAR-T is done in experienced centres, not as a casual outpatient infusion. When recognised early, many reactions can be managed. When ignored, they can become dangerous quickly.

5. Can an older patient receive Yescarta?

Age alone is not the deciding point. I have seen older patients who were fit enough for intensive treatment, and younger patients who were not. What matters is heart function, lung reserve, infections, daily activity level, neurological history and how aggressive the lymphoma is. The decision is about biological fitness, not the number written in the passport.

6. What happens if Yescarta does not work?

Then the next step depends on how much response there was, how quickly the lymphoma returned and what treatments have already been used. Some patients move to another targeted approach, an antibody-based treatment, a trial or supportive planning. It is a difficult moment, but it should not be discussed in vague terms. The scan, symptoms and blood recovery all guide the next conversation.

7. Why is a second opinion useful before CAR-T?

Because timing is everything. If CAR-T is discussed too late, the patient may become too unwell to receive it. If it is discussed too early, other reasonable options may be missed. A second opinion can help decide whether to move now, prepare the patient, use bridging therapy, or take another route first. That clarity is often the most valuable part of the consultation.

Important information

This page is for general medical orientation only. It is not a personal treatment recommendation and cannot replace a consultation with a haematologist or oncologist.

Yescarta may only be considered after review of the exact lymphoma type, previous treatment, current scans, blood results, organ function and overall condition.

Do not start, stop or change treatment without your treating physician.

To arrange a consultation regarding CAR-T therapy and Yescarta in Israel:

📞 +972-73-374-6844
📧 [email protected]
💬 WhatsApp: +972-52-337-3108